Omnix Medical bags €10.8m from EIC Accerator Fund
The money for the trial comes from the EIC Accelerator, for which last year 38 companies with potential breakthrough innovations were selected to...
AZD1222 claims 79% effecacy in pivotal US study
For exactly one day, the belief that AstraZeneca's COVID-19 vaccine AZD1222 may be better than its reputation lasted. But because the ailing vaccine...
Abingworth raises US-$465m for new life sciences fund
UK-US venture capitalist Abingworth yesterday announced the final closing of its 13th life sciences venture fund, ABV 8, at US$465m exceeding...
Cellectis and Cytovia in US$760m licence deal
Cytovia Therapeutics, Inc. and French Cellectis SAS have struck a licence deal to combine their different expertises in allogenic cancer cell...
MaxiVAX and Minaris Regenerative Medicine ink contract
Under the contract, Minaris will be responsible for the GMP manufacturing, freezing and shipping of MVX-ONCO-2, a cell-based immunotherapy for the...
Rentschler Biopharma launches gene therapy subsidiary
Monoclonal antibody specialist Rentschler Biopharma SE is moving forward with the expansion of its geographic footprint and technological porttfolio....
InteRNA Technologies secures €18.5m in Series B financing
Waterman Ventures and current shareholders Aglaia Oncology Funds and OostNL participated in the funding. The Utrecht-based...